Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Coenen who wrote (9418)	6/3/1998 9:59:00 AM
From: Scott H. Davis	Read Replies (2) \| Respond to of 14328

Bill, this is turning out positive - a back an forth, calm discussion of investment dynamics. Probably my last comment for a while. I get the impression that you, Greg and several others think my thinking is TA based. The current TA picture is not very encouraging, but I find that is just a confirmation of the other areas I was seeing. TRIBY's fundimentals do not currently work as a value play. The current and almost guarnateed flat intermediate term EPS (the market does not look very closely as more than 2 digits to the right of the .) and EPS downward surprises for several qtrs means that TRIBY does not work as a growth play with the growth crowd. Its a microcap ADR below $5.00 - therefore another large pool of potential investors wont touch it. There is no current hot catalyst, the story is now dated, and its in an industry most investors don't understand. Thus until TRIBY gets the HIV FDA, or starts growing EPS, it fails in so many aspects of market psychology. TRIBY has a very sound business development stratedgy they are sticking to and succeeding in growing the product and distribution base, and thus revenues. I'm glad we hear that management is now saying no more shares (and I hope they hold themselves to the same standard when it comes to exsecizing or granting (since granting options results in more shares on a fully diluted basis) more options this year) So maybe I'm clueless, (which is why I sometimes sign with IMSCO - In My Semi-Clueless Opinion), but I just don't see any catalyst that would result in material appreciation this year. Maybe you see a likely catalyst I'm missing. If so, Bill or anyone else, please enlighten me. Make a thorough presentation and I'll seriously consider it. Scott